Načítá se...
Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
Bone and soft tissue sarcomas account for approximately 15% of pediatric solid malignant tumors and 1% of adult solid malignant tumors. There are over 50 subtypes of sarcomas, each of which is notably heterogeneous and manifested by remarkable phenotypic and morphological variability. Anlotinib is a...
Uloženo v:
| Vydáno v: | Front Oncol |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8173120/ https://ncbi.nlm.nih.gov/pubmed/34094958 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.664853 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|